JP2024072289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024072289A5 JP2024072289A5 JP2023194564A JP2023194564A JP2024072289A5 JP 2024072289 A5 JP2024072289 A5 JP 2024072289A5 JP 2023194564 A JP2023194564 A JP 2023194564A JP 2023194564 A JP2023194564 A JP 2023194564A JP 2024072289 A5 JP2024072289 A5 JP 2024072289A5
- Authority
- JP
- Japan
- Prior art keywords
- image
- visible light
- fluorescence
- prism
- fluorescent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002073 fluorescence micrograph Methods 0.000 claims description 97
- 238000012800 visualization Methods 0.000 claims description 69
- 238000005259 measurement Methods 0.000 claims description 53
- 238000012545 processing Methods 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 31
- 230000005284 excitation Effects 0.000 claims description 23
- 238000003384 imaging method Methods 0.000 claims description 22
- 238000000691 measurement method Methods 0.000 claims description 17
- 238000000799 fluorescence microscopy Methods 0.000 claims description 15
- 238000012632 fluorescent imaging Methods 0.000 claims description 7
- 210000003414 extremity Anatomy 0.000 description 110
- 206010025282 Lymphoedema Diseases 0.000 description 35
- 208000002502 lymphedema Diseases 0.000 description 35
- 239000003795 chemical substances by application Substances 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 28
- 238000000576 coating method Methods 0.000 description 18
- 238000003745 diagnosis Methods 0.000 description 18
- 229960004657 indocyanine green Drugs 0.000 description 17
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 17
- 238000011282 treatment Methods 0.000 description 16
- 239000007850 fluorescent dye Substances 0.000 description 15
- 239000011248 coating agent Substances 0.000 description 14
- 230000003287 optical effect Effects 0.000 description 14
- 239000012530 fluid Substances 0.000 description 12
- 230000001926 lymphatic effect Effects 0.000 description 12
- 238000010586 diagram Methods 0.000 description 10
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 229960000907 methylthioninium chloride Drugs 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 238000011866 long-term treatment Methods 0.000 description 5
- 210000002751 lymph Anatomy 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 210000004324 lymphatic system Anatomy 0.000 description 4
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000000712 assembly Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000002310 reflectometry Methods 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- PDXNSXLPXJFETD-DYVQZXGMSA-N (2e)-2-[(2e)-2-[2-[4-[(2s)-2-[[4-[(2-amino-4-oxo-1h-pteridin-6-yl)methylamino]benzoyl]amino]-2-carboxyethyl]phenoxy]-3-[(e)-2-[3,3-dimethyl-5-sulfo-1-(4-sulfobutyl)indol-1-ium-2-yl]ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-3,3-dimethyl-1-(4-sulfobutyl)i Chemical compound OS(=O)(=O)CCCCN1C2=CC=C(S([O-])(=O)=O)C=C2C(C)(C)\C1=C/C=C\1C(OC=2C=CC(C[C@H](NC(=O)C=3C=CC(NCC=4N=C5C(=O)N=C(N)NC5=NC=4)=CC=3)C(O)=O)=CC=2)=C(\C=C\C=2C(C3=CC(=CC=C3[N+]=2CCCCS(O)(=O)=O)S(O)(=O)=O)(C)C)CCC/1 PDXNSXLPXJFETD-DYVQZXGMSA-N 0.000 description 1
- GRAVJJAQKJDGPM-UHFFFAOYSA-N 3-[2-[7-[3-(2-carboxyethyl)-1,1-dimethylbenzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]propanoic acid;bromide Chemical compound [Br-].OC(=O)CCN1C2=CC=C3C=CC=CC3=C2C(C)(C)\C1=C/C=C/C=C/C=C/C1=[N+](CCC(O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C GRAVJJAQKJDGPM-UHFFFAOYSA-N 0.000 description 1
- LWXYOERUKGQNKQ-IQDTYCCDSA-N 4-[2-[(1E,3E,5E,7Z)-7-[3-[6-[4-[(1R,4R,5aR,8aS,9R,12S,17aS,18S,20aS,21R,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54R,59R,62S,65S,74S,77R,80S,86S,92S)-9-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-39,62-bis(3-amino-3-oxopropyl)-24-benzyl-5a-[[(1S)-4-carbamimidamido-1-carboxybutyl]carbamoyl]-48,51,86,92-tetrakis(3-carbamimidamidopropyl)-17a,20a,33-tris(carboxymethyl)-27,30-bis[(1R)-1-hydroxyethyl]-74-[(4-hydroxyphenyl)methyl]-36-(1H-imidazol-4-ylmethyl)-45-methyl-8a-(2-methylpropyl)-12,42-bis(2-methylsulfanylethyl)-a,3,7a,10,10a,13,15a,18a,19,21a,22,25,28,31,34,37,40,43,46,49,52,61,64,70,73,76,79,82,85,88,91,94,97-tritriacontaoxo-2a,3a,6,7,12a,13a,56,57-octathia-2,6a,9a,11,14,16a,19a,20,22a,23,26,29,32,35,38,41,44,47,50,53,60,63,69,72,75,78,81,84,87,90,93,96,99-tritriacontazahexacyclo[57.41.10.84,54.421,77.014,18.065,69]docosahectan-80-yl]butylamino]-6-oxohexyl]-1,1-dimethylbenzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]butane-1-sulfonate Chemical compound CSCC[C@H](N)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]3CSSC[C@@H]4NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]5CCCN5C(=O)CNC(=O)[C@H](Cc5ccc(O)cc5)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCSC)NC1=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N3)NC(=O)[C@H](CCCCNC(=O)CCCCCN1\C(=C/C=C/C=C/C=C/C3=[N+](CCCCS([O-])(=O)=O)c5ccc6ccccc6c5C3(C)C)C(C)(C)c3c1ccc1ccccc31)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC4=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC2=O LWXYOERUKGQNKQ-IQDTYCCDSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000020312 Thickened skin Diseases 0.000 description 1
- -1 VGT-309 Chemical compound 0.000 description 1
- 241000244005 Wuchereria bancrofti Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000006036 elephantiasis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229960002143 fluorescein Drugs 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003702 image correction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229940074320 iso-sulfan blue Drugs 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000011271 lymphoscintigraphy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- NLUFDZBOHMOBOE-UHFFFAOYSA-M sodium;2-[[4-(diethylamino)phenyl]-(4-diethylazaniumylidenecyclohexa-2,5-dien-1-ylidene)methyl]benzene-1,4-disulfonate Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC=C(C=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 NLUFDZBOHMOBOE-UHFFFAOYSA-M 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- SFJHDNDCNUTGQM-UHFFFAOYSA-J tetrasodium (2E)-2-[(2E)-2-[3-[(E)-2-[3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indol-1-ium-2-yl]ethenyl]-2-(4-sulfonatophenoxy)cyclohex-2-en-1-ylidene]ethylidene]-3,3-dimethyl-1-(4-sulfonatobutyl)indole-5-sulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].CC1(C)\C(=C/C=C2\CCCC(\C=C\C3=[N+](CCCCS([O-])(=O)=O)c4ccc(cc4C3(C)C)S([O-])(=O)=O)=C2Oc2ccc(cc2)S([O-])(=O)=O)N(CCCCS([O-])(=O)=O)c2ccc(cc12)S([O-])(=O)=O SFJHDNDCNUTGQM-UHFFFAOYSA-J 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
Images
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263425397P | 2022-11-15 | 2022-11-15 | |
| US63/425,397 | 2022-11-15 | ||
| EP23205174.8 | 2023-10-23 | ||
| EP23205174.8A EP4371473B1 (en) | 2022-11-15 | 2023-10-23 | Method of measuring a fluorescence signal and of determining a 3d representation, image capturing and processing device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024072289A JP2024072289A (ja) | 2024-05-27 |
| JP2024072289A5 true JP2024072289A5 (https=) | 2025-04-17 |
Family
ID=88510906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023194564A Pending JP2024072289A (ja) | 2022-11-15 | 2023-11-15 | 蛍光シグナルを測定し３ｄ表現を決定する方法、画像取込み処理装置 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240156349A1 (https=) |
| EP (2) | EP4570170A3 (https=) |
| JP (1) | JP2024072289A (https=) |
| CN (1) | CN118044783A (https=) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110071403A1 (en) * | 2009-09-21 | 2011-03-24 | Board Of Regents Of The University Of Texas System | Functional near-infrared fluorescence lymphatic mapping for diagnosing, accessing, monitoring and directing therapy of lymphatic disorders |
| CN107398415B (zh) | 2011-09-20 | 2020-04-21 | 新宁研究院 | 超声换能器和制造超声换能器的方法 |
| US10101571B2 (en) * | 2012-07-10 | 2018-10-16 | Novadaq Technologies ULC | Perfusion assessment multi-modality optical medical device |
| US11564639B2 (en) * | 2013-02-13 | 2023-01-31 | The Trustees Of Dartmouth College | Method and apparatus for medical imaging using differencing of multiple fluorophores |
| US10986997B2 (en) * | 2013-12-31 | 2021-04-27 | Memorial Sloan Kettering Cancer Center | Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real time |
| JP6893877B2 (ja) * | 2014-10-29 | 2021-06-23 | スペクトラル エムディー, インコーポレイテッドSpectral Md, Inc. | 組織を分類するための反射モードマルチスペクトル時間分解型光学イメージングの方法および装置 |
| US20160235354A1 (en) * | 2015-02-12 | 2016-08-18 | Lymphatech, Inc. | Methods for detecting, monitoring and treating lymphedema |
| JP6645591B2 (ja) * | 2017-01-11 | 2020-02-14 | 株式会社島津製作所 | 蛍光イメージング装置および蛍光イメージングシステム |
| NL2018494B1 (en) * | 2017-03-09 | 2018-09-21 | Quest Photonic Devices B V | Method and apparatus using a medical imaging head for fluorescent imaging |
| JP6747576B2 (ja) * | 2017-03-17 | 2020-08-26 | 株式会社島津製作所 | イメージング装置 |
| EP4183328A1 (en) * | 2017-04-04 | 2023-05-24 | Aranz Healthcare Limited | Anatomical surface assessment methods, devices and systems |
| WO2020148726A1 (en) * | 2019-01-17 | 2020-07-23 | Moleculight Inc. | Modular system for multi-modal imaging and analysis |
| KR102277779B1 (ko) * | 2019-08-22 | 2021-07-15 | (주)에스원바이오 | 림프부종 진단을 위한 정보제공 방법 |
| WO2021038729A1 (ja) * | 2019-08-27 | 2021-03-04 | 株式会社島津製作所 | 治療支援装置および治療支援方法 |
| KR102395600B1 (ko) * | 2020-02-28 | 2022-05-06 | (주)에스원바이오 | 림프부종 진단을 위한 씨암형 촬영장치 |
-
2023
- 2023-10-23 EP EP25174636.8A patent/EP4570170A3/en active Pending
- 2023-10-23 EP EP23205174.8A patent/EP4371473B1/en active Active
- 2023-11-14 CN CN202311516712.4A patent/CN118044783A/zh active Pending
- 2023-11-15 JP JP2023194564A patent/JP2024072289A/ja active Pending
- 2023-11-15 US US18/510,123 patent/US20240156349A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10136806B2 (en) | Image display method, image display apparatus, and storage medium | |
| CN107851176A (zh) | 光学成像系统及其方法 | |
| JP2018514349A (ja) | 血流及び灌流の画像化及び定量化を行うマルチスペクトルレーザ画像化（ｍｓｌｉ）方法及びシステム | |
| CN106572792A (zh) | 用于多光谱成像的方法和部件 | |
| EP4371472B1 (en) | Image capturing and processing device | |
| JP2024072288A5 (https=) | ||
| EP4371471B1 (en) | Method of measuring a fluorescence signal and a visible light image, image capturing and processing device | |
| CN117202834A (zh) | 医用成像设备、尤其是立体内窥镜或立体外窥镜 | |
| JP2024072286A5 (https=) | ||
| JP2016512133A (ja) | 網膜血管系の解析により疾患を検出する方法 | |
| JP2020524572A (ja) | 内視鏡イメージングのためのシステム、および、画像を処理するための方法 | |
| JP2014073207A (ja) | 眼科撮影装置 | |
| CN120112207A (zh) | 医学成像设备和用于医学成像的方法 | |
| EP4372680A1 (en) | Computer based clinical decision support system and method for determining a classification of a lymphedema induced fluorescence pattern | |
| KR102277779B1 (ko) | 림프부종 진단을 위한 정보제공 방법 | |
| Pruitt et al. | A high-speed hyperspectral laparoscopic imaging system | |
| JP2024072287A5 (https=) | ||
| US9854963B2 (en) | Apparatus and method for identifying one or more amyloid beta plaques in a plurality of discrete OCT retinal layers | |
| JP2024072289A5 (https=) | ||
| JP2024072289A (ja) | 蛍光シグナルを測定し３ｄ表現を決定する方法、画像取込み処理装置 | |
| JP7584983B2 (ja) | 医用画像処理装置及びその制御方法、並びにプログラム | |
| JP2026500611A (ja) | 蛍光イメージングのための動き補正付き背景差分 | |
| Taniguchi et al. | Improving convenience and reliability of 5-ALA-induced fluorescent imaging for brain tumor surgery | |
| US20260090722A1 (en) | Systems and methods for real time, quantitative, hyperspectral and optical property imaging for in vivo intraoperative multiplex molecular guided surgery | |
| Murawski et al. | Measurement of corneal neovascularisation with the use of image processing techniques |